There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DBV Technologies SA – American (NASDAQ:DBVT) and Ultragenyx (NASDAQ:RARE) with bullish sentiments.
DBV Technologies SA – American (DBVT)
In a report released yesterday, Derek Archila from Stifel Nicolaus maintained a Buy rating on DBV Technologies SA – American, with a price target of $35. The company’s shares opened today at $18.58.
Archila said:
“We continue to like the risk/reward (+135%/-20%) for shares at these levels as we think the Street is modeling a <50% probability of success (POS) Viaskin peanut will have its BLA accepted and receive a positive panel/approval. We think the stock could see a +15-20% move on BLA acceptance alone (as investors' POS assumptions improve), which is expected by year end, and we remain positive Viaskin peanut will ultimately receive approval next year. Key Points From his perspective, Dr. Sampson believes Viaskin peanut's efficacy demonstrated a meaningful signal at one year (~1/3 of patients were responders), but more importantly, provided increased desensitization over time in its open-label extension studies."
According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.3% and a 28.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Pacira Pharmaceuticals, and Aimmune Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DBV Technologies SA – American with a $30.67 average price target.
See today’s analyst top recommended stocks >>
Ultragenyx (RARE)
In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ultragenyx. The company’s shares opened today at $47.55, close to its 52-week low of $41.67.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.2% and a 46.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Ultragenyx has an analyst consensus of Strong Buy, with a price target consensus of $80.67, a 69.7% upside from current levels. In a report issued on October 26, Raymond James also maintained a Buy rating on the stock with a $70 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
